133 related articles for article (PubMed ID: 38782015)
1. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M; Hansen T; Rom D; Geist MA; Blaettler T; Camu W; Kuzma-Kozakiewicz M; van den Berg LH; Morales RJ; Chio A; Andersen PM; Pradat PF; Lange D; Van Damme P; Mora G; Grudniak M; Elliott M; Petri S; Olney N; Ladha S; Goyal NA; Meyer T; Hanna MG; Quinn C; Genge A; Zinman L; Jabari D; Shoesmith C; Ludolph AC; Neuwirth C; Nations S; Shefner JM; Turner MR; Wuu J; Bennett R; Dang H; Sundgreen C;
Lancet Neurol; 2024 Jul; 23(7):687-699. PubMed ID: 38782015
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive
Benatar M; Wuu J; Andersen PM; Atassi N; David W; Cudkowicz M; Schoenfeld D
Neurology; 2018 Feb; 90(7):e565-e574. PubMed ID: 29367439
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial.
Machado PM; McDermott MP; Blaettler T; Sundgreen C; Amato AA; Ciafaloni E; Freimer M; Gibson SB; Jones SM; Levine TD; Lloyd TE; Mozaffar T; Shaibani AI; Wicklund M; Rosholm A; Carstensen TD; Bonefeld K; Jørgensen AN; Phonekeo K; Heim AJ; Herbelin L; Barohn RJ; Hanna MG; Dimachkie MM;
Lancet Neurol; 2023 Oct; 22(10):900-911. PubMed ID: 37739573
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Meininger V; Genge A; van den Berg LH; Robberecht W; Ludolph A; Chio A; Kim SH; Leigh PN; Kiernan MC; Shefner JM; Desnuelle C; Morrison KE; Petri S; Boswell D; Temple J; Mohindra R; Davies M; Bullman J; Rees P; Lavrov A;
Lancet Neurol; 2017 Mar; 16(3):208-216. PubMed ID: 28139349
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.
Cudkowicz ME; Titus S; Kearney M; Yu H; Sherman A; Schoenfeld D; Hayden D; Shui A; Brooks B; Conwit R; Felsenstein D; Greenblatt DJ; Keroack M; Kissel JT; Miller R; Rosenfeld J; Rothstein JD; Simpson E; Tolkoff-Rubin N; Zinman L; Shefner JM;
Lancet Neurol; 2014 Nov; 13(11):1083-1091. PubMed ID: 25297012
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.
Cudkowicz M; Genge A; Maragakis N; Petri S; van den Berg L; Aho VV; Sarapohja T; Kuoppamäki M; Garratt C; Al-Chalabi A;
Lancet Neurol; 2021 Oct; 20(10):821-831. PubMed ID: 34536404
[TBL] [Abstract][Full Text] [Related]
9. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.
; Morrison KE; Dhariwal S; Hornabrook R; Savage L; Burn DJ; Khoo TK; Kelly J; Murphy CL; Al-Chalabi A; Dougherty A; Leigh PN; Wijesekera L; Thornhill M; Ellis CM; O'Hanlon K; Panicker J; Pate L; Ray P; Wyatt L; Young CA; Copeland L; Ealing J; Hamdalla H; Leroi I; Murphy C; O'Keeffe F; Oughton E; Partington L; Paterson P; Rog D; Sathish A; Sexton D; Smith J; Vanek H; Dodds S; Williams TL; Steen IN; Clarke J; Eziefula C; Howard R; Orrell R; Sidle K; Sylvester R; Barrett W; Merritt C; Talbot K; Turner MR; Whatley C; Williams C; Williams J; Cosby C; Hanemann CO; Iman I; Philips C; Timings L; Crawford SE; Hewamadduma C; Hibberd R; Hollinger H; McDermott C; Mils G; Rafiq M; Shaw PJ; Taylor A; Waines E; Walsh T; Addison-Jones R; Birt J; Hare M; Majid T
Lancet Neurol; 2013 Apr; 12(4):339-45. PubMed ID: 23453347
[TBL] [Abstract][Full Text] [Related]
10. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
Al-Chalabi A; Shaw PJ; Young CA; Morrison KE; Murphy C; Thornhill M; Kelly J; Steen IN; Leigh PN;
BMC Neurol; 2011 Sep; 11():111. PubMed ID: 21936930
[TBL] [Abstract][Full Text] [Related]
11. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
[TBL] [Abstract][Full Text] [Related]
12. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol.
Kalmar B; Lu CH; Greensmith L
Pharmacol Ther; 2014 Jan; 141(1):40-54. PubMed ID: 23978556
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Aggarwal SP; Zinman L; Simpson E; McKinley J; Jackson KE; Pinto H; Kaufman P; Conwit RA; Schoenfeld D; Shefner J; Cudkowicz M;
Lancet Neurol; 2010 May; 9(5):481-8. PubMed ID: 20363190
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
[TBL] [Abstract][Full Text] [Related]
15. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Riva N; Mora G; Sorarù G; Lunetta C; Ferraro OE; Falzone Y; Leocani L; Fazio R; Comola M; Comi G;
Lancet Neurol; 2019 Feb; 18(2):155-164. PubMed ID: 30554828
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.
Mengel E; Patterson MC; Da Riol RM; Del Toro M; Deodato F; Gautschi M; Grunewald S; Grønborg S; Harmatz P; Héron B; Maier EM; Roubertie A; Santra S; Tylki-Szymanska A; Day S; Andreasen AK; Geist MA; Havnsøe Torp Petersen N; Ingemann L; Hansen T; Blaettler T; Kirkegaard T; Í Dali C
J Inherit Metab Dis; 2021 Nov; 44(6):1463-1480. PubMed ID: 34418116
[TBL] [Abstract][Full Text] [Related]
18. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
Lacomblez L; Bensimon G; Leigh PN; Guillet P; Meininger V
Lancet; 1996 May; 347(9013):1425-31. PubMed ID: 8676624
[TBL] [Abstract][Full Text] [Related]
19. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis.
Cudkowicz ME; Shefner JM; Simpson E; Grasso D; Yu H; Zhang H; Shui A; Schoenfeld D; Brown RH; Wieland S; Barber JR;
Muscle Nerve; 2008 Jul; 38(1):837-44. PubMed ID: 18551622
[TBL] [Abstract][Full Text] [Related]
20. Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.
Park SB; Vucic S; Cheah BC; Lin CS; Kirby A; Mann KP; Zoing MC; Winhammar J; Kiernan MC
EBioMedicine; 2015 Dec; 2(12):1916-22. PubMed ID: 26844270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
